Trial Profile
A Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Reduced Left-ventricular Ejection Fraction (LVEF≤ 45%) After Acute Myocardial Infarction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulacimstat (Primary)
- Indications Left ventricular dysfunction
- Focus Registrational; Therapeutic Use
- Acronyms CHIARA MIA 2
- Sponsors Bayer
- 11 Sep 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Trial has been completed in Czech Republic.
- 15 Mar 2018 Planned End Date changed from 21 Sep 2018 to 5 Sep 2018.